Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study

References

• Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
   PubMed Web of Science ®Google Scholar
• Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39:448-53
   PubMed Web of Science ®Google Scholar
• Adams E, Daniel S, Chandran A, et al. A population-based survey and physician assessment of the characteristics and prevalence of fibromyalgia. Arthritis Rheum 2013;65(10 Suppl):S55
   Google Scholar
• Arnold LM, Clauw DJ, Dunegan LJ, et al. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc 2012;87:488-96
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clin Proc 2011;86:907-11
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Pauer L, Winkelmann A, Arsenault P, et al; on behalf of the A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-52
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, et al; and the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
   PubMed Web of Science ®Google Scholar
• Lyrica (pregabalin) capsules [prescribing information], 2012. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=561 [Last accessed 27 December 2013]
   Google Scholar
• World Health Organization. Adherence to long-term therapies – evidence for action, 2003. Available at: http://apps.who.int/medicinedocs/en/d/Js4883e/6.1.html [Last accessed 7 January 2014]
   Google Scholar
• Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-34
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527-39
   PubMed Web of Science ®Google Scholar
• New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease, 2009. Available at: http://www.nehi.net/writable/publication_files/file/pa_issue_brief_final.pdf [Last accessed 19 May 2014]
   Google Scholar
• Chew M, Plotka A, Alvey C, et al. Effect of food and dose on pregabalin controlled release pharmacokinetics in healthy volunteers. J Pain 2013;14:S66
   PubMed Web of Science ®Google Scholar
• Chew ML, Plotka A, Alvey CW et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: Effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig 2014, DOI 10.1007/s40261-014-0211-4. [epub ahead of print]
   Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Williams DA, Arnold LM. Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S86-97
   PubMedGoogle Scholar
• Assumpção A, Pagano T, Matsutani LA, et al. Quality of life and discriminating power of two questionnaires in fibromyalgia patients: Fibromyalgia Impact Questionnaire and Medical Outcomes Study 36-Item Short-Form Health Survey. Rev Bras Fisioter 2010;14:284-9
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
   PubMed Web of Science ®Google Scholar
• Arnold LM, Zlateva G, Sadosky A, et al. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 2011;12:260-7
   PubMed Web of Science ®Google Scholar
• Pleil AM, Coyne KS, Reese PR, et al. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue – the BSW. Value Health 2005;8(Suppl 1):S25-34
   PubMedGoogle Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
   PubMed Web of Science ®Google Scholar
• Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain 2014;30:379-90
   Google Scholar
• Nasser K, Kivitz AJ, Maricic MJ, et al. Twice daily vs once nightly dosing of pregabalin for fibromyalgia: a double-blind, randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken) 2014;66:293-300
   Google Scholar
• McQuay HJ, Derry S, Moore RA, et al. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 2008;135:217-20
   PubMed Web of Science ®Google Scholar
• Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain 2009;25:797-807
   PubMed Web of Science ®Google Scholar
• Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain 2008;136:232-4
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar